MenQuadfi is a vaccine used to protect adults and children from the age of 12 months against invasive meningococcal disease caused by four groups of the Neisseria meningitidis bacteria (group A, C, W, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning). The vaccine contains substances from the outer coat of N. meningitidis bacteria.
Therapeutic Indication
### Therapeutic indication MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07AH08
ATC Item
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid |
EMA Name
MenQuadfi
Medicine Name
MenQuadfi
Aliases
N/ANo risk management plan link.
